Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Lithium Americas Corp (LAC) Price & Performance

Quest Diagnostics IncTrade
Lithium Americas CorpTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Lithium Americas Corp — how do they compare? Quest Diagnostics Inc trades at $237.94 (market cap $26.21B), while Lithium Americas Corp trades at $3.25 (market cap $1.18B). The key difference: Quest Diagnostics Inc is far larger — about 22.2× Lithium Americas Corp's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.

DGXLAC
Market Cap
$26.21B$1.18B
Sector
HealthBasic Materials
52-Week High
$238.50$10.05
52-Week Low
$173.49$2.71
Enterprise Value
$31.97B$1.29B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.

The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.

Lithium Americas Corp

Lithium Americas (LAC) trades at $3.25 with mixed technical signals showing a bullish overall trend but neutral oscillators. The company reported negative profitability metrics with ROE at -11.35% and net income of -$122.09M for 2025, though it secured $175M financing for Thacker Pass construction. Recent earnings show volatility with two beats and one miss in the last four quarters.

LAC faces significant execution risks with substantial capital expenditures needed, but analyst sentiment remains positive with 7 buy ratings and no sell recommendations. The stock's valuation at 0.88 P/B suggests potential upside if lithium demand recovers, though negative cash flow from operations and high investing outflows present near-term challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC